Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01419236 · ClinicalTrials.gov registry record · Phase 2

A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels

A Phase 2 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
76
Enrollment target

NCT01419236: Completed Phase 2 study, sponsored by Eli Lilly and Company.

NCT01419236 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 76 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01419236, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
76 participants
Enrollment target

Study Summary

The purpose of this study is to see if testosterone solution 2% can impact symptoms of ejaculatory dysfunction in men with low testosterone.

Primary Outcome

MSHQ-EjD-SF: 4 item, self-reported questionnaire assessing ejaculatory dysfunction. MSHQ-EjD-SF Ejaculatory Function Score: sum of scores for questions (Q)1 through Q3 about frequency and strength of ejaculations and volume of ejaculate for sexual activity attempts during past month. Ejaculation frequency was rated 1 (could not ejaculate) to 5 (all the time); strength and volume from 0 (could not ejaculate) to 5 (as strong/much as it always has been). Total Ejaculatory Function Score ranged from

Interventions

  • DRUG Placebo Solution
  • DRUG Testosterone Solution 2%

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2011-08
Est. Completion 2013-12
Phase Phase 2
Eli Lilly and Company

1,341 total trials

What the finished NCT01419236 record still lists

NCT01419236 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo Solution is the first listed.

NCT01419236 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01419236 about?

NCT01419236 is a clinical study titled "A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels". The purpose of this study is to see if testosterone solution 2% can impact symptoms of ejaculatory dysfunction in men with low testosterone.

What is the current status of trial NCT01419236?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2011-08. Estimated completion is 2013-12.

What interventions are being tested in trial NCT01419236?

The interventions under investigation include: Placebo Solution (DRUG), Testosterone Solution 2% (DRUG).

Who is sponsoring clinical trial NCT01419236?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01419236's enrollment target sits among peer trials

76 893rd of 2000 higher than 1,101 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02615184 · 76 participants · Phase 2

    A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

  • NCT02821741 · 76 participants · NA

    Effects of External Ear Stimulation on Pain Perception and Mood

  • NCT03019757 · 76 participants

    Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

  • NCT03353584 · 76 participants · NA

    Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01419236, the US trial registry maintained by the National Library of Medicine. NCT01419236 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.